Zhejiang CONBA Pharmaceutical Co., Ltd.SSE: 600572

Report for Q1 2026

Apr 23, 2026 · Issued by Zhejiang CONBA Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Apr 23, 2026

On 6ix: 6ix.com/news/report-for-q1-2026-71

Report for Q1 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Zhejiang CONBA Pharmaceutical Co., Ltd. on 6ix

Earlier from Zhejiang CONBA Pharmaceutical

Announcement on Subsidiary Obtaining Drug Registration Certificate for Telmisartan Amlodipine Tablets (III)Apr 10
Announcement on Voluntary Exercise Results of Stock Option Incentive Plan in Q1 2026 and Share ChangesApr 2
Indicative Announcement on Restricted Exercise Period of Stock Option Incentive Plan of 2022Apr 1
Announcement on Results of Shareholding Reduction by ShareholdersMar 11
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% ScaleMar 7

Later from Zhejiang CONBA Pharmaceutical

Announcement on Obtaining Drug Registration Certificate for Blonanserin Tablets by its SubsidiaryMay 9
Announcement on Resolutions of the 2025 Annual General MeetingMay 14
Announcement on Convening Performance Briefing for 2025 and Q1 2026Jun 6
Announcement on the Public Listing and Transfer of 100% Equity Interest in Dongyang ConbaJun 9
Announcement on Implementation of Dividend Distribution for 2025Jun 17

All Zhejiang CONBA Pharmaceutical news releases

Follow Zhejiang CONBA Pharmaceutical into a list and get an email when it puts out news.

Follow Zhejiang CONBA Pharmaceutical